AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
- Announced initiation of dosing of anti-Abeta vaccine ACI-24.060 in the biomarker Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s disease and individuals with Down syndrome
- Received regulatory clearance to initiate an adaptive, biomarker-based Phase 2 anti-alpha-synuclein vaccine ACI-7104 in patients with early Parkinson’s disease
- Phase 2 API ADAD study results presented at AAIC 2022 showed numerical differences across multiple endpoints favoring crenezumab anti-Abeta antibody over placebo none were statistically significant
- Tau positron emission tomography (PET) tracer PI-2620 advanced into late-stage development for which we have recognized milestone revenue from our partner Life Molecular Imaging
- Follow-on grant from the Michael J. Fox Foundation paves the way for enhanced studies of alpha-synuclein PET tracer ACI-12589
- Four clinical readouts delivered to date; three more expected by year-end
- Strong end of quarter financial position of CHF 140.5 million is now expected to extend for operations into Q3 2024 without considering potential milestone payments
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported results for the third quarter ended September 30, 2022, and provided a corporate update.